Investment Pitches

Pitch Summary:
Oracle contributed to performance in the second quarter, as the company reported strong quarterly results that highlighted continued strong demand for the company’s OCI infrastructure, sustained growth in the company’s SaaS apps business, and accelerating growth trends in the cloud database segment. Management highlighted RPO growth of over 100%, which speaks to continuing demand for Oracle’s infrastructure and software products over a multi-year period.

BSD Analysis:
Oracle has managed to turn “legacy enterprise vendor” into “quiet AI arms dealer” faster than most skeptics can update their models. OCI’s architecture is actually well-suited to GPU-heavy AI workloads, and multi-year infrastructure deals with hyperscalers and big enterprises are starting to show up in the numbers. At the same time, the core database franchise remains one of the most entrenched moats in software — ripping Oracle out is still career-ending behavior in many IT shops. The free cash flow profile is excellent, capex is high but targeted, and buybacks are steadily shrinking the float. Oracle doesn’t need to be the coolest name in AI; it just needs to remain the most embedded. Right now, it’s doing exactly that.

Pitch Summary:
Quest Diagnostics is a leading U.S. diagnostic health information provider, serving about 50% of hospitals and physicians, 33% of adults, and over 90% of insured lives. With $9.9B revenue and $1.9B EBITDA in 2024, it is expected to grow to $11.2B revenue, $2.3B EBITDA, and $1.2B FCF by 2026. The business benefits from a duopolistic industry structure with LabCorp, giving it significant pricing power and growing outsourcing from hospitals. Its recurring, habitual testing creates sticky customer relationships and reliable revenues, reinforced by network effects. Secular tailwinds include worsening U.S. population health, rising demand for chronic disease monitoring, and heightened societal awareness of diagnostic testing post-COVID. The company’s services are cost-effective relative to downstream interventions, making it well positioned as payers push for cost savings. Quest also pays a 1.8% dividend and repurchases shares opportunistically. The author argues the market underappreciates Quest’s durable growth profile, estimating EPS of $10.50+ in 2026 and $11.50+ in 2027, supporting a valuation of 20x EPS, or $230/share. Quest is framed as a “great business at a cheap price with unfortunate tailwinds,” suitable as a long-term compounder.

BSD Analysis:
BSD view: Quest Diagnostics is a high-quality, defensive compounder trading below intrinsic value, supported by structural duopoly, secular tailwinds in testing demand, and strong recurring revenues. Risks remain in reimbursement and regulatory shifts, but its scale, network, and cost-effectiveness make it an advantaged long-term hold. Current valuation offers upside with limited downside given cash flows and dividend support.

Pitch Summary:
Anebulo Pharma announced a reverse stock split (1:2500–1:7500) designed to cash out small holders at $3.50/share and deregister from SEC reporting. While management estimated ~$1.8M in total costs, trading activity exploded post-announcement: ~20M shares traded versus ~19k daily average, mostly in small blocks, suggesting thousands of “arb” investors piled in to exploit the split. If even 1,000 such accounts exist, ANEB’s cash obligation could balloon to $8.75M+, jeopardizing liquidity given $13.3M cash (3/31) and ~$7M trailing 9-month losses. The proxy also permits “double dipping” by holding <7,500 shares across multiple brokerages, further increasing exposure. Unlike Psychemedics (PMDI), which secured a backstop, ANEB disclosed no such financing. This resembles Parker Drilling’s 2019 fiasco, where terms had to be revised unfavorably after arbitrageurs overwhelmed the plan. Borrow costs are ~12% on IBKR, limiting shorting appeal, but if the plan collapses, the stock could retrace toward its pre-announcement $1.83 (~45% downside). Holders like Nantahala (3M shares at $1.94) and Mangrove (2.5M at $1.43) likely sold into the spike. Risks include management pushing through regardless or later repricing a go-dark deal, but near term the setup favors shorts expecting cancellation or dilution of the terms.

BSD Analysis:
BSD view: this is less a biotech fundamental story than a capital structure “special situation.” Core question: can ANEB fund unexpectedly massive cash-out obligations without external capital? If not, expect either amendment (lower price, narrower split ratio) or outright cancellation. Arbitrageurs’ exploitation of the split loophole is a red flag that management may have underestimated market response. Liquidity is thin, so position sizing and borrow costs are crucial. Risk: company secures financing or is willing to burn most of its cash to go dark, which would minimize short-term downside but damage long-term operations.

Pitch Summary:
Femasys is a U.S. medtech microcap focused on minimally invasive, office-based solutions for women’s reproductive health, with two flagship products: FemaSeed (infertility device) and FemBloc (non-surgical permanent contraception). After 20 years of R&D and underfunding, the company has four FDA-cleared and CE-marked products, a U.S. sales team, and EU approval for FemBloc. FemaSeed launched in 2024, though sales remain nascent, while FemBloc is in a pivotal U.S. trial with FDA filing expected in 2026. The addressable markets are large ($3B near-term, $20B longer-term) and the Essure precedent (Conceptus acquired by Bayer for $1.1B) highlights potential upside. Liquidity risk looms, with a convertible note maturity in late 2025, but Femasys has repeatedly raised capital. Positives include strong IP (~200 patents), in-house manufacturing, high margins, regulatory momentum, and early commercial traction. Risks include execution on commercialization, financing needs, regulatory approval, and physician adoption challenges. If successful, the company could follow a similar trajectory to Conceptus, implying multibagger potential despite heavy dilution.

BSD Analysis:
BSD view: Femasys offers an asymmetric long with high clinical and commercial risk but significant upside if FemBloc and FemaSeed scale. Regulatory wins and a newly built sales force mark a turning point, yet near-term liquidity risk and a history of delays temper confidence. The Essure precedent both validates the demand and underscores risks of safety/market acceptance. With a ~$28M market cap, optionality is compelling for investors who can tolerate volatility, but execution and financing are critical to realizing potential.

Pitch Summary:
Forward Air is the subject of an active strategic alternatives process that investors expect will culminate in a sale to a financial sponsor. The company, historically a quality expedited LTL operator, was hurt by the Omni acquisition but now faces strong activist pressure and board changes that cleared obstacles to a sale. At the June 2025 AGM, shareholders voted against three entrenched directors, approved reincorporation in Delaware, and paved the way for Clearlake and other PE buyers to participate. Reuters has since confirmed multiple bids from large sponsors including Clearlake, Platinum Equity, EQT, Apollo, and American Industrial Partners, suggesting a competitive process. Shares trade at ~$30.50, below the ~$40 deal price many expect, implying ~30% near-term upside with potential for more if bidding intensifies. Precedent asset-light transportation M&A transactions have fetched 12–20x multiples, giving further valuation support. A July 8-K granting incentives to the new Chairman tied to a successful review adds confidence that a transaction is imminent. With Q2 earnings set for August 11, timing pressure exists to announce a deal before then. While risks include a failed process or extended timeline, the setup points toward an imminent sale at a premium.

BSD Analysis:
BSD view: Forward Air represents a classic event-driven arbitrage trade. Board and governance reforms, confirmed PE interest, and Reuters-sourced bidding activity reduce deal risk meaningfully. The valuation gap between current price and expected takeout levels suggests asymmetric upside with limited downside given shareholder activism and strategic asset value. Key watchpoints are earnings timing, sponsor discipline, and regulatory clearance, but catalysts line up in the next 1–2 months, making this a timely special situation long.

Pitch Summary:
Lock‑up violation via shell resale; virtual façade & sham deals; barred broker is head of BD; governance & audit red flags; insider enrichment.

BSD Analysis:
BMF Reports allege Aether violated lock-up agreements via undisclosed resale through shell entities, while overstating its VR/AI business footprint. The company shows limited genuine operations, with revenue primarily tied to related-party transactions. Governance red flags dominate, including opaque offshore structures. The short thesis suggests ATHR is more a capital-markets story than an operating company, with downside driven by regulatory scrutiny and market loss of confidence.

Pitch Summary:
Single-China supplier, no differentiation, minimal aftermarket; delisting risk; $0.5 M cash vs. $1–2 M quarterly burn; China tariffs amid weak demand.

BSD Analysis:
Sunshine Research flags Flux Power’s reliance on a single China-based supplier and limited differentiation in lithium battery packs for forklifts and industrial equipment. Margins remain thin and customer adoption lags larger competitors. Capital intensity, recurring dilution, and supplier dependency create execution risk. The stock trades more on EV battery enthusiasm than on fundamentals, leaving downside if supply chain issues emerge or financing dries up.

Pitch Summary:
Around 18 months ago now we discovered Nu Holdings. Its low unit-costs, customer obsession and disruptor mindset in the lazy world of consumer banking immediately sparked our interest. Simply put Nu Holdings has the best unit costs in global full service banking (75% below peers and still falling). It uses these low costs not to boost profits but instead to offer customers better interest rates (e.g. Nu's 12% Mexican deposit rate vs c.5% offered by peers). Because of this and its high customer service focus, Nu is rightly loved by consumers. This can be seen in the speed with which 118m customers have flocked to it but also in its great Net Promoter Scores (NPS). The global banking industry consumer offering has not really changed much in 50 years. (Accounts, loans, branches, poor interest rates, little customer service or value for money and add-on digital apps). We think that might be about to change. Companies like Wise will tackle niches like foreign exchange, but Nu can offer a far more efficient full suite of banking products at great prices. Importantly its offering uses the Scale Economy Shared business model that we admire and seek out. We remind readers that it is this business model which has proven so powerful in retailing (Costco) and online (Amazon). Of course, there is a way to go before Nu can be included in such a rarified list of proven Gorilla businesses, but we think it has a good chance of success. We think Nu has the right building blocks and culture in place to challenge not just banks in Latin America, but globally. Nu has real dedication to low-units costs combined with a desire to innovate and share such cost efficiencies with its customers. It is also obsessed with delighting the customer. These traits when combined create a powerful flywheel model that has been super successful in other industries and geographies. No one (except Wise) is trying to take this model into financial services, until now. All this is symptomatic of the disruptor business models we seek out and what we look for in a business model with a long runway of growth. Indeed, when we wrote about 'Supernatural Compounders' in our Nirvana piece, Nu was at the forefront of our mind. In our recent investor meeting we listed six traits we look for in such a business (Nu possesses all six): • A visionary founder • Who re-thinks their industry – solving a hard problem • ...to give customers a more compelling offering • Is low unit-cost driven and customer obsessed • Has a huge runway of growth ahead • Makes good/great ROICs that enable self-funded growth Two further points interest us about Nu. The first is the giant scope of growth in front of it as arguably the whole global banking industry is ripe for this type of disruption. The second is how much the company's current earnings are depressed, suggesting the shares are not as expensive as they look. To compete with Nu, incumbent banks will need future cost bases that are c.75% lower than today's and more importantly a management mentality that passes much of that new efficiency on to customers. This would mean a re-basing of profits to much lower levels. From today's starting point of incumbent bank culture and customer/shareholder relations this will be almost impossible to achieve. Our confidence in this statement comes from our observations in so many other sectors that have been disrupted in this way (UK pubs, ecommerce, supermarkets, airlines, streaming). No matter how high the IQ is of incumbent banking CEO or how good the hired consultants are, the end result is so often the same. Readers may highlight differences between Brazilian/Mexican banking vs other countries, thus implying our simple extrapolation of Nu's model is maybe flawed. There are always regional and sector differences, but customer desire for 'value for money' is a philosophy that is both timeless and travels the world over – of that we are certain. We also note how powerful and well established the banks in Brazil Nu competed with to win its 100m customers were (e.g. Santander and Bank Itau). In short, we think Nu has the brand, customer service, culture and low unit cost base to win market share in many, many, countries. The company's recent commentary on its potential for global growth is interesting. They know they need global, not local IT systems to export their model worldwide. These take money and time to build. Nu are expensing such future growth costs today and tell us they should be ready by 2026/7. Not only do we think Nu has a long runway of growth ahead of it we think it is already the best banking business model in the world today. A recent Nu investor presentation showed the group's ROE of 27% (but this includes early stage set up costs in Mexico and Columbia). This 27% level is also calculated off a central capital base that is way in excess of the bank's long term needs. Adjusting for such excess capital (and start-up costs) Nu's ROE is c.60%. Remember this is a bank, a fully regulated and capitalised bank, not just a payment platform. The most recent Q1 25 net income reported by Nu was $557m, annualised $2.2bn. This is the figure used in the 27% ROE calculations above. It also suggests a headline valuation of 28x PE. Readers might therefore assume all future growth is fully priced in. We do not agree. The chart below shows the ARPU the company earns from each user of $11.2 (per month). It also shows that the average mature Brazilian bank has an APRU of $43. The longer customers have been with Nu the higher their ARPU (as they use more products). With super low and stable unit-costs each dollar increase in ARPU is highly profitable to the company. Particularly so, when such growth is just driven by existing customers maturing in their relationship with the company. At a c.60% incremental profit rate were the company's ARPU to be $15 not $11.2 its annual profits today would be $4.8bn not $2.2bn. Adjusting for this reduces the Dec24 PE from 28x to 13x. Remember this is a historic multiple for a company growing 25-40% pa. Also, one with a runway to keep growing at similar rates for many years into the future. Despite its rapid growth to date, the company still only has a tiny market share of banking gross profit pools in Brazil (5%) and Mexico (<1%). This provides a glimpse as to how big Nu's profit pool might be just by deepening its existing market positions. Future expansion in other geographies only expands its growth runway further. We think Nu a powerful future global business deploying a proven disruptor model. It is also led by its founder (David Velez). He is a perfect example of the sort of leader we wish to align our capital with. Visionary, ambitious and passionate about the right things. He always talks about: • Lowest unit costs • Outstanding customer service • Great product innovation • Developing an excellent culture Disruptor businesses like Nu are, by definition, hard to forecast and much can change along the way. But we are in the probability game, not the certainty game. How high a probability do we attach to the idea that Nu might be able to carry on growing at high rates for a long period? And what price might we pay for a chance of such an outcome? • Nu's look through PE (using a more mature ARPU) is c.13x we suggest. • Very prudently we could assume it will trade on a similar multiple 20y out (Likely more if it were still a dominant growing business with good products and ROE's) o If so, our investment return will match the compounding the company itself achieves • So how fast might the company grow? o Maybe today's ROE (of 30-50%) will moderate to 25% o If all of that were reinvested for growth at similar rates of return, then… o The entity we own a portion of could grow at c.25%pa • A quick glance of a compound interest table tells us… o That at a 25% growth rate each £100 invested in Nu Holdings today will be worth… o … £8,600 in twenty years' time We hope you can see why we are excited about our investment in Nu Holdings.

BSD Analysis:
Holland Advisors presents a compelling bull case for Nu Holdings as a 'supernatural compounder' that could disrupt global banking through its scale economy shared model. The manager's thesis centers on Nu's exceptional unit cost advantage (75% below peers) which it passes to customers via superior deposit rates, creating a powerful customer acquisition flywheel that has attracted 118 million users. The fund views Nu as possessing all six traits of exceptional growth companies: visionary founder leadership, industry disruption solving hard problems, compelling customer value proposition, low-cost obsession, massive growth runway, and strong self-funded ROICs. Holland argues that Nu's current 28x PE is misleading due to depressed earnings from global expansion investments and low customer ARPU maturity, suggesting a normalized 13x multiple when adjusting for mature customer monetization patterns. The manager sees significant market share expansion opportunities, noting Nu holds only 5% of Brazilian banking profits and less than 1% in Mexico, with global expansion capabilities being built for 2026-27 deployment. With founder David Velez leading the charge and ROE potential of 60% (adjusted for excess capital), Holland projects 25% annual growth rates that could generate 86x returns over twenty years, positioning Nu as a potential banking industry disruptor comparable to Amazon's retail transformation.

Pitch Summary:
Brookfield Corporation is a holding company that manages investment strategies in direct real estate, asset management, private equity, and insurance. The company's longstanding expertise comes from its heritage in real estate investing, where it continues to hold an extensive portfolio of high-profile and trophy properties in the office, retail, and hospitality sectors. Through the firm's ownership of Brookfield Asset Management (BAM), it provides institutional investment portfolios with a significant focus on real estate, including projects related to energy and infrastructure. BAM's key holdings in these business lines include: Brookfield Renewable Partners, Brookfield Infrastructure Partners, and Brookfield Property Group. Brookfield Corp. is also in the process of growing its wealth solutions business through insurance-related offerings in annuities. The advantages of real estate in an environment of unstable currencies can be seen through two lenses. First, rental contracts with tenants generally have escalation clauses that compensate the lessor for rising inflation, thereby creating a built-in hedge for future cash flows. Second, because real estate is a hard asset, itself composed of various commodities, it has a readily discernible replacement value that can be calculated with some level of agreement in the marketplace. These two factors tend to protect real estate assets against depreciating currencies over longer periods of time. In addition to the core fundamental inflation hedges in its business, we are also drawn to Brookfield's focus on growth in the real estate sector through investment activities related to AI data centers and the increasing demand for electricity driven by the digital economy. Importantly, the company's global scale enables it to make these investments across various geographies and political jurisdictions, thereby diversifying its exposure to a single currency or economic policy. For instance, the company is investing in the buildout of AI data centers across Europe with key projects in Sweden and France, as well as in the United States. While we believe the two drivers we described above represent attractive fundamental qualities in this economic environment, and for that matter, future ones, we can also cite the scale at which Brookfield can deploy capital as a competitive advantage in this economy. The simple fact is that at the holding company level, it houses $155 billion in capital on its balance sheet, controls $110 billion in insurance float, and its asset management companies carry an AUM of approximately $1 trillion. We believe these levels of assets enable Brookfield and its subsidiaries to participate at their discretion in what is shaping up to be a significant global capex cycle in capital-intensive investments, as new technologies related to AI, electricity demand, and even country-specific stories such as India spur a widespread need for investment and the necessary financing. In other words, we believe the company is well-positioned to deploy capital at scale. Doing so, should sustain its profile as a growing company in a world that is embracing new technologies yet becoming increasingly fragmented and self-reliant. In conclusion, we believe Brookfield offers a unique combination of downside protection and scalable upside in a rapidly evolving global economy.

BSD Analysis:
The manager presents a compelling bull case for Brookfield Corporation centered on its role as an inflation hedge and growth vehicle in an uncertain currency environment. With the USD declining 12% in the first half of 2025, the manager views Brookfield's real estate portfolio as offering natural protection through rental escalation clauses and hard asset replacement values. The investment thesis emphasizes Brookfield's strategic positioning in high-growth sectors, particularly AI data centers across multiple geographies including Sweden, France, and the US. The manager highlights the company's massive scale advantage with $155 billion in balance sheet capital, $110 billion in insurance float, and $1 trillion in assets under management. This capital deployment capability positions Brookfield to capitalize on the emerging global capex cycle driven by AI infrastructure and electricity demand. The geographic diversification across political jurisdictions reduces single-currency exposure risk. The manager views this combination of defensive characteristics and growth optionality as particularly attractive in the current fragmented global economy.

Pitch Summary:
Watches of Switzerland is a retailer and partner to Rolex and other luxury watch brands. Rolex only sells through authorized retailers like WOSG, which gives WOSG far superior economics to a typical retailer because of lengthy customer waiting lists, no online competition, and no inventory risk. WOSG has around 50% share of all Rolex sales in the UK and 10% share in the US where it is the leader consolidating the industry. Management are competent, experienced, and well incentivized, with CEO Brian Duffy owning nearly £30mm worth of stock. We first bought shares around £3.5 last year, it peaked at £6.0 late last year and now trades around £3.5 again and on 10x FCF. We think intrinsic value in three years will be more than double today's price. The stock has declined 34% this year on concerns that US tariffs on Switzerland, currently 10% but initially set at 31%, will lead to a decline in demand and profitability for Rolex and other Swiss watch brands. In early July WOSG guided to EBIT margins falling from 9.0% to 8.0-9.0% in the year ending April 2026, assuming a 10% tariff. While the reporting on US/Swiss negotiations has been encouraging, in our three-year valuation we assume tariffs increase to 20% and that WOSG's margins fall further to 7.5%. Tariffs may go higher than 20% in the interim, but Switzerland has virtually no tariffs on the US, is a willing negotiator, and several other nations focused on negotiating rather than retaliating have eventually seen their tariffs reduced below Liberation Day rates. We therefore think a 20% 'final' tariff in three years is a reasonable assumption. Some investors at that point may even be pricing in a new administration that further reduces or eliminates tariffs. While we accept there remains great uncertainty on tariffs and some shareholders have sold the stock as a result, we continue to believe that investors underappreciate the resilience of Rolex and Patek Philippe, which account for around 75% of WOSG's profits by our estimate. Both brands have substantial pricing power and benefit from waiting lists that our data suggests continuing to lengthen in the US. WOSG seems to agree, with management in early July guiding to 6-10% organic growth for the coming year despite the macro headwinds. Importantly, we believe our thesis that the US offers a large market for WOSG to gain market share and redeploy capital at attractive returns remains intact. Over the last six months the total number of Rolex stores in the US declined from 276 to 258 as Rolex continued its decades-long strategy of reducing its store count and reallocating watches to more desirable stores. The number of WOSG stores selling Rolexes increased from 19 to 21 in the same period. WOSG's strategy to gain share also includes buying stores run by mom & pops who are unable or unwilling to invest million(s) of dollars to refurbish stores up to Rolex's standards. WOSG stated on its earnings call that tariffs (and we suspect the continued reduction in store count) are now making some mom & pops more willing sellers. The company also declined to renew its buyback, citing the potential need to use cash for acquisitions. We think investors tend not to price in the value of acquisitions until they happen, which means WOSG's long runway to deploy capital in the US is underappreciated. The company currently has ND/EBITDA of just 0.5x, and we estimate that taking this up to even 1.0x would fund over £200mm of acquisitions over the next three years when excess cash generation is accounted for. At 10x FCF that buys £20mm of FCF, a nearly 20% boost compared to WOSG's FCF of £107mm in fiscal 2025. We continue to believe that WOSG's economics are closer to a subsidiary of Rolex than a retailer, that the company is a structural winner with a long runway of high single-digit organic growth and ability to deploy capital at 15-20% returns, and that 10x FCF is a very attractive price for the stock. We recently added to our position.

BSD Analysis:
The manager maintains a strong bull thesis on Watches of Switzerland despite the stock declining 34% year-to-date due to US tariff concerns on Swiss imports. The investment case rests on WOSG's unique position as an authorized Rolex retailer with superior economics driven by customer waiting lists, no online competition, and zero inventory risk. With 50% UK market share and 10% US share, the company benefits from Rolex's strategy of reducing total store count while reallocating inventory to preferred partners like WOSG. The manager believes the market has overreacted to tariff risks, modeling a conservative 20% final tariff rate and 7.5% EBIT margins versus current 9% levels. Key to the thesis is WOSG's US expansion opportunity through acquisitions of mom-and-pop stores unable to meet Rolex's capital requirements for store refurbishments. With net debt of only 0.5x EBITDA, the company could fund over £200mm in acquisitions, potentially boosting free cash flow by nearly 20%. The manager views WOSG's economics as more akin to a Rolex subsidiary than a traditional retailer, expecting continued high single-digit organic growth and 15-20% returns on deployed capital. At 10x FCF, the manager believes intrinsic value will more than double within three years.

Pitch Summary:
Judges Scientific is a serial acquirer of niche scientific instrument businesses in the UK. The company has delivered 22% returns on incremental capital for 20 years by our estimates and 25% p.a. shareholder returns. Cofounder David Cicurel remains CEO and is someone with high integrity, a clear customer focus, strong capital allocation skills and owns shares worth around 200x his base salary. While the stock trades at an optically high 23x EV/FCF we believe it can still deliver a 25% IRR going forwards. We first bought shares in Judges at £61/shr and it trades at £81/shr today. We recently published a 35-page report on the company here. The businesses Judges acquires tend to be the leaders in attractive niches, face little competition, and have significant pricing power. Examples of products sold include vacuum chambers and ultra-low temperature cooling systems costing anywhere from thousands of pounds up to £1mm for large systems. The businesses have delivered organic EBIT growth of 9% p.a. for 20 years post-acquisition. Revenues are spread out across the US, EU, and China and customers tend to be universities, research institutions, and R&D departments. Despite having these qualities, Judges acquires businesses for an average of just 5x EBIT. It can do this because it buys small private businesses with £1-10mm in revenues and founders prefer to sell to Judges instead of private equity because Judges takes a hands-off approach post-acquisition with no cost cuts, very limited integration, and no debt loaded onto the company. That allows the acquired companies to continue running themselves in a decentralized structure. CEO Cicurel's integrity is also key to Judges paying low multiples. He does not go back on his word and start extracting synergies once an acquisition is complete, and behaves well throughout the acquisition process. The reputation Judges has generated among founders will be hard for another acquirer to replicate, and probably impossible for private equity. We believe that Judges has a long runway to continue acquiring small scientific instrument businesses. The UK scientific instrument industry benefits from great universities in Oxford, Cambridge, and the London colleges that provide a continuous pipeline of startups. The biggest challenge to Judges continuing its success is likely to be a potential change in management. Cicurel is 76, although we think it is unlikely he retires any time soon. It is more likely that he continues to gradually reduce his role, as he has done over the last decade, by moving up to Chairman in the next few years. Judges have substantial experience successfully handling leadership changes at their subsidiary businesses, and we believe that experience is paying off as the company is well positioned to manage its own transition. Business Development Director Tim Prestidge, Commercial Director Ian Wilcock, and Acquisitions Executive Rik Armitage have been hired over the last couple years and taken on increasing roles. Prestidge came from another UK serial acquirer in a similar space while Wilcock and Armitage worked in the same industry at Oxford Instruments. All have strong technical and business knowledge and will likely be compensated far more if the stock does well. Judges trades at 23x EV/FCF and although that is not an optically cheap multiple, we believe the company can continue reinvesting 100% of earnings at 20%+ incremental returns. That means investors should be able to earn a 20%+ IRR assuming no change in multiple. However, serial acquirers with a track record like Judges often trade at a higher multiple and Judges has done so the past too, so we think prospective returns could be significantly higher.

BSD Analysis:
The manager presents a compelling bull case for Judges Scientific, a UK-based serial acquirer of niche scientific instrument businesses. The investment thesis centers on the company's exceptional 20-year track record of generating 22% returns on incremental capital and 25% annual shareholder returns under founder-CEO David Cicurel's leadership. The manager values Cicurel's integrity and capital allocation skills, noting his significant skin in the game with shares worth 200x his base salary. Despite trading at a seemingly expensive 23x EV/FCF multiple, the manager believes the company can deliver 25% IRRs going forward by continuing to acquire businesses at attractive 5x EBIT multiples and reinvesting 100% of earnings at 20%+ returns. The competitive advantage stems from Judges' reputation among founders who prefer selling to them over private equity due to their hands-off, decentralized approach post-acquisition. Key risks include management succession as Cicurel is 76, though the manager believes the company is well-positioned for transition with experienced new hires. The manager sees a long runway for growth given the UK's strong university ecosystem that provides a continuous pipeline of scientific instrument startups.

Pitch Summary:
RLH was introduced to Airo Group in early 2024 as the company was pursuing a SPAC transaction. Both the SPAC and Airo were actively seeking capital. We were impressed by Airo's fundamentals — the company was EBITDA-positive, operating in a highly thematic sector (military-grade drones), and led by a capable management team. After conducting due diligence, we concluded that Airo could service debt on a standalone basis and that the SPAC merger had a high likelihood of closing. In the first quarter of 2024, RLH, alongside a group of co-investors we introduced, invested in both the SPAC sponsor and Airo directly through a structured bridge loan. RLH's speed in conducting diligence, ability to quickly fund, and deep capital markets knowledge made us the right partner for a complex and time-sensitive transaction. By August 2024, Airo was prepared to complete its SPAC transaction. However, due to unfavorable market conditions, the capital raise fell short of expectations. After discussions with management, Airo pivoted toward a traditional IPO, which we believed would better reflect the company's value and raise more capital. As part of this pivot, we restructured our investment to include incremental economics — additional equity consideration and interest — to reflect the added duration and complexity. In June 2025, Airo completed its IPO, raising $69 million in a deal led by Cantor Fitzgerald and BTIG. The offering priced at $10 and was well received, with shares rising 140% in the first day of trading. The decision to delay and pursue a regular-way IPO ultimately maximized value for all stakeholders. As of July 22, 2025, based on the current trading price of $23.84, RLH generated a total net return of 322% and a net multiple on invested capital (MOIC) of 4.2x. Please note that our shares are subject to a six-month lockup and are marked using a conservative liquidity discount.

BSD Analysis:
RLH Capital presents a compelling case study of their investment in Airo Group, a military-grade drone manufacturer that demonstrated strong fundamentals with EBITDA-positive operations. The manager's thesis centered on Airo's position in the highly thematic defense technology sector, particularly unmanned aerial vehicles, combined with capable management and the ability to service debt independently. RLH's strategic approach involved providing bridge financing through both SPAC sponsor investment and direct company funding, leveraging their speed of execution and capital markets expertise. When market conditions deteriorated for the SPAC transaction, management pivoted to a traditional IPO strategy, which RLH supported as a value-maximizing decision. The IPO execution was successful, raising $69 million at $10 per share with strong first-day performance showing 140% gains. RLH achieved exceptional returns with a 322% net return and 4.2x multiple on invested capital, validating their investment thesis. The position remains subject to a six-month lockup period, with shares currently trading at $23.84, demonstrating continued market confidence in the company's prospects.

Pitch Summary:
Amazon's robotics network—now numbering over 1 million autonomous robots across more than 300 fulfillment centers—is nothing short of an industrial revolution in progress. Since acquiring Kiva in 2012, Amazon has scaled up its in-house robotics stack with a clarity of vision and execution that we believe remains underappreciated by the market. Their latest innovation, Sequoia, shortens order processing time by 25% and improves inventory handling by 75%. Equally impressive is Amazon's foundation model, DeepFleet, which has cut travel time across its robotic fleet by 10%. These aren't marginal gains—they're margin catalysts. In fact, our analysis indicates that robotics is playing a pivotal role in Amazon's push to double its operating margins in North America from ~5% to 10–11% over time. This is a slow-motion tectonic shift—one that favors patient capital. With this, Amazon is building a greenhouse for innovation, compounding structural efficiency and financial oxygen.

BSD Analysis:
Nightview Capital positions Amazon as an underappreciated robotics and automation leader driving significant margin expansion. The fund emphasizes Amazon's massive scale with over 1 million autonomous robots across 300+ fulfillment centers, representing an industrial revolution in progress. They highlight specific performance metrics including 25% faster order processing and 75% improved inventory handling through the Sequoia innovation. The investment thesis centers on robotics as a margin catalyst, with the DeepFleet foundation model delivering 10% travel time reductions across the robotic fleet. The managers project operating margin expansion from 5% to 10-11% in North America, driven by structural efficiency gains. They view this as a slow-motion tectonic shift favoring patient capital, with Amazon building a 'greenhouse for innovation' that compounds structural advantages. The thesis reflects confidence in Amazon's underappreciated robotics execution since the 2012 Kiva acquisition.

Pitch Summary:
In July, Tesla flipped the switch. Its robotaxi network—powered by the company's Full Self-Driving (FSD) platform—officially began commercial service in Austin, Texas. While the headlines haven't yet caught up, we believe this marks a generational milestone in both transportation and artificial intelligence. This is no longer a simulation. No longer a slide deck. No longer a promise of what's to come. What matters now is the ability to scale the project — First slowly and then with increasing acceleration. Tesla now operates the world's first vision-based, end-to-end autonomous mobility network using consumer-owned vehicles. And because the software stack was built entirely in-house—from silicon to inference engine—Tesla controls the unit economics in a way no other player can. With FSD deployed at scale, Tesla's cost to serve a mile approaches zero. Unlike traditional ride-hailing, there's no driver to compensate. Unlike competitors like Waymo or Cruise, there's no expensive Light Detection And Ranging (LiDAR) or (eventually) remote operator. Tesla vehicles already ship with the hardware required. It's a software unlock. Every incremental robotaxi mile becomes a margin story. Think of it this way: Uber's driver takes ~75% of the fare. Tesla takes 100%. At maturity, we estimate robotaxi gross margins could exceed 70%. That's better than Apple's iPhone, better than AWS, better than almost any business with massive potential scale we've studied in modern history. The global personal transport market is estimated at $10 trillion. That includes taxis, ride-hailing, car ownership, public transport—anything that moves people. Capturing just 10% of that market with high-margin autonomous rides could generate $1 trillion in annual revenue. While that is obviously high we genuinely believe it is within the realm of reason. Autonomous transportation has the potential to be that big. Let's say Tesla reaches 100 billion robotaxi miles per year globally (a conservative estimate by 2040). At $0.50/mile net revenue, that's $50 billion per year in high-margin software income. At $1.00/mile, that's $100 billion. And that's before we include licensing FSD to third-party fleets. We believe Tesla is not building a product. It is building infrastructure—much like AWS did for cloud, or Apple did for mobile. And as infrastructure, the upside becomes nonlinear. Austin is the first node in a network that could soon span the globe. The next cities—Houston, Miami, Los Angeles, Phoenix—are in Tesla's sights. And unlike every other player in autonomy, Tesla already has millions of vehicles on the road and billions of miles of real-world training data. In our view, Tesla is building the most capital-efficient mobility platform in history, powered by vertically integrated AI, and accelerated by a deeply underappreciated energy business. Tesla's humanoid robot, Optimus, has now reached its third generation, with ongoing trials in internal factory settings. While there have been setbacks—engineer departures, component delays, and recalibrated timelines (similar to what we see with the Model 3 launch in 2019)—we remain intrigued by the overall velocity of progress. Tesla's competitive advantage lies not only in its vertical integration, but in its AI software stack, which continues to train across multiple real-world environments. As we've written before: Tesla is building an 'AI flywheel'—each product reinforcing the next. The humanoid bet will require immense execution, but we believe if the thesis plays out, it could offer the potential of a massively high-reward. In our view, it represents the farthest edge of what's possible in applied automation.

BSD Analysis:
Nightview Capital presents Tesla as a transformational infrastructure play centered on the commercial launch of its robotaxi network in Austin. The fund views this as a generational milestone in transportation and AI, emphasizing Tesla's unique position as the world's first vision-based, end-to-end autonomous mobility network. The investment thesis highlights Tesla's superior unit economics with near-zero marginal costs and 100% fare capture versus traditional ride-hailing's 25% take rate. The managers project potential 70%+ gross margins at maturity, exceeding Apple's iPhone and AWS profitability. They estimate the $10 trillion global transport market opportunity could generate $50-100 billion in annual high-margin software revenue by 2040. The thesis emphasizes Tesla's vertical integration advantage, existing vehicle fleet, and billions of miles of training data. Additionally, they view the Optimus humanoid robot as representing the frontier of applied automation, creating an 'AI flywheel' effect across Tesla's product ecosystem.

Pitch Summary:
We've been closely following Alibaba for over 15 years—through its IPO, meteoric rise, regulatory turbulence, and now its strategic reset. Over that time, we've come to understand the company not just as China's Amazon, but as a foundational piece of the country's digital economy. Its reach spans e-commerce, logistics, cloud computing, and fintech, with a scale and infrastructure footprint that is nearly impossible to replicate. After years of growth and volatility, what we now see is a business that's leaner, more focused, and trading at a valuation that no longer reflects its long-term earnings power. What makes this moment particularly compelling is the convergence of a depressed multiple and a maturing opportunity set. While sentiment around China and its tech sector remains cautious, Alibaba continues to generate strong free cash flow and dominate key verticals in one of the largest consumer markets in the world. As the regulatory environment stabilizes and the company leans into shareholder returns, we believe the risk-reward dynamic has meaningfully shifted. It's rare to find a business of this caliber, with this level of optionality, trading at such a compressed valuation. We're re-engaging not just because of where Alibaba has been—but because of where it still has the potential to go.

BSD Analysis:
Nightview Capital presents a compelling re-engagement thesis for Alibaba based on valuation compression and strategic repositioning. The fund's 15-year observation period provides deep institutional knowledge of the company's evolution from IPO through regulatory challenges to its current strategic reset. They emphasize Alibaba's foundational role in China's digital economy, spanning e-commerce, logistics, cloud computing, and fintech with irreplaceable scale and infrastructure. The investment rationale centers on the convergence of depressed multiples with a maturing opportunity set and strong free cash flow generation. The managers highlight the company's leaner, more focused approach and dominance in key verticals within the world's largest consumer market. They anticipate regulatory environment stabilization and increased shareholder returns as catalysts. The thesis reflects confidence in a meaningfully shifted risk-reward dynamic for a business of exceptional caliber trading at compressed valuations.

Pitch Summary:
Wynn Resorts (WYNN) and Las Vegas Sands (LVS) provide a calculated bridge to the Chinese economy—without the direct exposure and risk that typically come with mainland investments. These companies maintain significant assets in Macau, the world's largest gaming hub, which functions as a unique access point to Chinese consumer demand. In the wake of COVID, there has been a great deal of uncertainty about a potential rebound. But we see an optimistic picture emerging: a rebound in tourism, a gradual reorientation of China's domestic economy toward consumption, and an underappreciated opportunity to capture upside in Asian discretionary spending. What makes this position compelling is the structure—U.S.-based corporations benefiting from Chinese growth dynamics while operating under the legal and financial protections of American capital markets. As Chinese wealth creation resumes and regional travel flows normalize, we believe companies like WYNN and LVS are positioned to be long-term beneficiaries. These are plays on the next phase of China's consumer story—but executed through entities governed by robust disclosure standards, shareholder protections, and capital allocation discipline. In a world increasingly defined by geopolitical tension, this dual exposure—Asian growth through American frameworks—offers asymmetric return potential with a margin of safety.

BSD Analysis:
Nightview Capital presents Las Vegas Sands as a strategic investment vehicle for accessing Chinese economic recovery while maintaining U.S. regulatory protections. The fund's thesis centers on LVS's significant Macau operations, positioning it as a bridge to Chinese consumer demand without direct mainland exposure risks. The managers anticipate a tourism rebound and China's economic reorientation toward consumption as key drivers. They emphasize the structural advantage of U.S.-listed entities benefiting from Chinese growth dynamics while operating under superior governance frameworks. The investment rationale highlights Macau's status as the world's largest gaming hub and an underappreciated opportunity in Asian discretionary spending. The thesis reflects confidence in Chinese wealth creation resumption and normalization of regional travel flows. This positioning offers asymmetric upside potential with enhanced safety through American capital market protections.

Pitch Summary:
Wynn Resorts (WYNN) and Las Vegas Sands (LVS) provide a calculated bridge to the Chinese economy—without the direct exposure and risk that typically come with mainland investments. These companies maintain significant assets in Macau, the world's largest gaming hub, which functions as a unique access point to Chinese consumer demand. In the wake of COVID, there has been a great deal of uncertainty about a potential rebound. But we see an optimistic picture emerging: a rebound in tourism, a gradual reorientation of China's domestic economy toward consumption, and an underappreciated opportunity to capture upside in Asian discretionary spending. What makes this position compelling is the structure—U.S.-based corporations benefiting from Chinese growth dynamics while operating under the legal and financial protections of American capital markets. As Chinese wealth creation resumes and regional travel flows normalize, we believe companies like WYNN and LVS are positioned to be long-term beneficiaries. These are plays on the next phase of China's consumer story—but executed through entities governed by robust disclosure standards, shareholder protections, and capital allocation discipline. In a world increasingly defined by geopolitical tension, this dual exposure—Asian growth through American frameworks—offers asymmetric return potential with a margin of safety.

BSD Analysis:
Nightview Capital presents a compelling thesis for Wynn Resorts as a strategic proxy for Chinese economic recovery and consumer spending growth. The fund views WYNN as offering exposure to China's transition from a manufacturing-based to consumer-driven economy while maintaining the safety of U.S. regulatory frameworks. The investment rationale centers on Macau's position as the world's largest gaming hub and a unique gateway to Chinese consumer demand. The managers anticipate a tourism rebound and normalization of regional travel flows as key catalysts. They emphasize the structural advantage of accessing Chinese growth dynamics through U.S.-listed entities with superior governance and shareholder protections. The thesis reflects confidence in China's wealth creation resumption and the underappreciated opportunity in Asian discretionary spending. This positioning offers asymmetric upside potential while mitigating direct mainland China investment risks.

Pitch Summary:
The author argues that Talen Energy is a compelling buy because rising demand from data-center buildouts—especially in the PJM grid region where Talen operates—should drive increased power demand over the next several years. Talen benefits from a diversified generating fleet including nuclear capacity, which the author highlights as a stable, high-quality power source able to meet growing grid demands. The firm has hedged a large portion of its 2025 and 2026 power output, providing revenue visibility. Based on company guidance, the author expects free cash flow per share to double or triple in the coming two years; under that scenario, Talen’s 2026E P/FCF multiple may fall into the 12.3–20.5× range, making the shares appear undervalued relative to cash-flow generation potential. The thesis is that Talen offers a “quality + value + secular growth” combination, fueled by structural tailwinds from data-center demand and robust liquidity/hedging, justifying a bullish stance.” From a fundamental investor’s perspective, Talen Energy operates in the utility/independent power-producer space — a capital-intensive but regulated/contractual-like business model with stable demand. The rise in data-center power demand, especially in regions like PJM, aligns well with Talen’s asset footprint and gives it a structural growth tailwind, rather than relying solely on volatile merchant power price cycles. Its hedging program for 2025–2026 is a prudent risk-management move that reduces near-term revenue volatility and provides a smoother cash-flow outlook. Given its diversified generation mix (including nuclear and presumably other baseload assets), Talen may weather energy-market fluctuations better than pure merchant generators. If free cash flow per share truly doubles or triples, the implied 12–20× P/FCF looks relatively attractive for a utility-like company, especially one exposed to growth themes (data centers, electrification, increased power demand). That said, key risks remain: (1) power sector regulation and environmental/climate policy could impact legacy fossil/coal assets; (2) demand forecasts (e.g., from data centers) may not fully materialize or shift geographically; (3) the valuation depends heavily on execution — hedging is helpful but growth in FCF/share requires stable operations, disciplined capital expenditures, and favorable electricity pricing and capacity markets. Additionally, being in the somewhat cyclical independent power-producer sub-industry means there’s still exposure to commodity-price and demand-cycle risks, unlike regulated utilities. Overall, Talen appears to be an interesting hybrid: a utility-adjacent growth-levered play — but much depends on demand growth, execution, and regulatory developments."

BSD Analysis:
The PJM power market is undergoing a structural reset as data center load growth collides with slow permitting, plant retirements, and transmission bottlenecks. Talen’s competitive position is advantaged by asset location and reliability, particularly its nuclear capacity, which provides baseload power that hyperscalers increasingly prioritize. Secular AI-driven demand appears durable and geographically concentrated, creating multi-year pricing power rather than a transient spike. Hedging tempers near-term upside but meaningfully reduces downside risk, supporting balance-sheet strength through the transition. The principal risks are regulatory intervention and political pressure if power prices remain elevated, which could cap long-term returns. Valuation still reflects historical cyclicality rather than a structurally higher clearing price regime. If free cash flow inflects as guided, the equity could re-rate as investors recalibrate normalized earnings power. In that scenario, TLN shifts from a levered commodity generator to a scarce infrastructure asset with durable cash generation.

Actual Post Content:
Reasons to own $TLN: - over the past year, grid planners have almost doubled their 5-year demand forecast mostly due to the data center demand - most data centers are located in the PJM grid (Northeast US) right where most of Talen’s capacity is - it owns high-quality nuclear asset and others providing one of the most reliable power sources in the grid - Talen has hedged 67% and 31% of prices for 2025 and 2026, respectively - $TLN expects to grow its free cash flow per share (FCF/share) by 2x - 3x in the next two years - based on that guidance its 2026E P/FCF is expected to a range of 20.5x - 12.3x, making it a quality and undervalued play.

URL: https://x.com/AlphaArkInvest/status/1876267299704877385

Pitch Summary:
The author argues they recently added TruBridge (TBRG) despite its checkered M&A history, because a new governance coalition (led by Pinetree Capital Ltd. and another firm) has taken a meaningful stake and secured board seats. They believe the governance changes — board declassification, poison-pill removal, and more transparency — mark a pivot toward value-oriented discipline. With the company projecting robust EBITDA in 2025 and modest capex, the author calculates a potential ~13.5× earnings multiple, translating into a ~7.5% yield on equity. They expect modest annual earnings growth (5%+), margin improvement (e.g., via outsourcing BPO operations), and possibly multiple expansion if execution ramps. In their view, TruBridge is a turnaround small-cap play with undervalued equity and structural tailwinds in the outsourced healthcare revenue-cycle management (RCM) industry. While not a high-IRR pick today, they believe it’s a reasonable, conservative bet on a potential re-rating over several years.

BSD Analysis:
TruBridge presents an interesting risk-reward profile. The company operates in the healthcare IT/services sector — specifically revenue-cycle management and hospital billing support — a segment with secular tailwinds as smaller hospitals face staffing pressure and increasing regulatory complexity. Outsourced RCM remains underpenetrated, and TruBridge’s service mix (Financial Health + Patient Care) gives it recurring revenue and stickiness. The recent deleveraging (net debt ~$144 million as of Q3 2025, net leverage ~2.2×) and improved EBITDA margin — along with positive free cash flow and a growing cash balance — provide a solid financial foundation. If management executes on cost-savings, operational optimization, and client growth, there is room for both earnings growth and multiple expansion. However, risks remain material: the company’s history of poor acquisitions signals a governance/discipline issue — and activist-backed governance reset may take time to translate. The small-cap nature implies limited liquidity, and continued reliance on hospital outsourcing trends means any macro headwinds or changes in healthcare regulation reimbursement could hurt. Finally, the lack of a well-known competitive moat may limit long-term upside absent consolidation or differentiation.

Actual Post Content:
Why I Added TruBridge $TBRG to My Portfolio As always: This is not investment advise. Do your own research. Below is my interpretation of the information available. Some of you may have noticed that I’ve recently added TruBridge $TBRG to my portfolio. At first glance, this might seem like an odd pick. After all, TruBridge has a history of poor capital allocation, including a few acquisitions that, in hindsight, destroyed more value than they created. But something has changed — and I believe the current setup is worth a closer look. Let’s start with the past. A History of Missteps TruBridge, formerly known as CPSI, doesn’t exactly have a stellar track record when it comes to M&A. One of the most notable examples is their 2016 acquisition of Healthland, a company owned by private equity firm Francisco Partners. TruBridge paid around $250 million for the business — two-thirds in debt, one-third in equity — despite the fact that Healthland was loss-making on approximately €120 million in revenue. It was a classic case of overpaying for a struggling business. Unfortunately, this wasn’t an isolated incident. In 2023, TruBridge acquired Viewgol for $36 million upfront with a potential $31.5 million earn-out — valuing the company at about 8x EBITDA (based on $4.5 million). But when you consider that Viewgol was generating only $1.5 million in net income, the multiple on earnings creeps well above 20x. They repeated the pattern with their acquisition of HRG, which was producing $3.6 million in EBITDA. While the purchase price wasn’t publicly disclosed, the cash flow statement suggests they spent roughly $43 million that year, implying a multiple of around 12x EBITDA. Clearly, capital allocation has been a weak spot for TruBridge. So why am I investing now? What’s Changed The turning point came in mid-2024, when L6 Holdings and Pinetree Capital ($PNP.TO) started building a stake in the company. Not long after, they entered into a cooperation agreement with TruBridge that introduced significant strategic and governance changes. This collaboration included: Two board appointments: – Dris Upitis (L6/Ocho) – Jerry Canada, a former executive at Harris Computer These aren’t passive seats — Upitis joined the Nominating & Governance Committee, and Canada sits on the Compensation Committee. Governance improvements: The company agreed to declassify the board, enabling annual elections for all directors starting in 2026. They also terminated their poison pill, creating flexibility for future strategic alternatives. Structured alignment with L6 and Pinetree: – Both parties committed to a standstill (no activist moves) – They agreed to vote in line with the cooperation agreement – They established a framework for ongoing access to internal company data, fostering transparency and alignment – All of this suggests that a new chapter is beginning — one with better oversight, improved discipline, and clearer long-term intent. The Setup Today I believe what we’re seeing is the early phase of an operational turnaround — potentially leading to a sale within the next 5 years. The groundwork is there: better governance, activist influence and early moves toward margin improvement (e.g. outsourcing BPO operations to India). Let’s take a quick look at valuation: Market Cap: ~$330 million Debt: ~$160 million EBITDA guidance for 2025: $60–66 million CapEx: ~$1.2 million (PPE) and ~$16 million (intangibles) Interest expense: ~$12 million Assuming the low end of guidance: EBT = $60m – $12m – $16m – $1.2m = $30.8 million EAT (after ~21% tax) ≈ $24.3 million That implies a ~13.5x earnings multiple, or a ~7.5% yield on equity. Now add to that: – At least 5% annual earnings growth (likely conservative, given optimization potential) – Potential multiple expansion if execution improves – Structural tailwinds in RCM outsourcing, especially as hospitals increasingly look to cut costs Final Thoughts This isn’t my highest-IRR idea — yet. But I like the setup: a company with a history of underperformance, now under pressure (and support) from smart, engaged investors who have a clear track record of turning businesses around. Valuation is undemanding, margins are improving, governance is tightening — and for once, the company seems pointed in the right direction. In addition to that, take into account that L6 / $PNP.TO topped up their holding at $29 in Q1 2025 vs $22 where it's trading today.

URL: https://x.com/investmentideen/status/1947212786246865181?s=43&t=pQIybbYGPwfAIRjp-OZu8w

Pitch Summary:
@blondesnmoney argues that CBL is misunderstood by bears who focus on low-quality properties while overlooking the company’s balance sheet flexibility, refinancing progress, and non-recourse debt structure. The recent sale of the Promenade Open Air Center generated a substantial gain and provides cash that can be freely deployed, likely resulting in a large special dividend. Combined dividends and buybacks in 2025 represent a meaningful 15% cash yield. The company has refinanced major loans at lower rates, extended maturities, and passed key term-loan tests, signaling improving financial health. The author emphasizes that non-recourse debt prevents a repeat of CBL’s prior bankruptcy, as the company can walk away from underperforming assets. With a large cash pile, low valuation at ~4.5× FFO, and strong CMBS/CLO demand enabling ongoing refinancing, CBL may be positioned for meaningful upside. Bears, in contrast, require multiple negative macro and management decisions to break right simultaneously.

BSD Analysis:
CBL represents a distressed-quality retail REIT operating in a challenged property category, but its capital structure today is materially different from its pre-bankruptcy era. Non-recourse, property-specific debt meaningfully caps downside, giving management the option to surrender weak assets rather than jeopardize the enterprise. The Promenade sale at an 8.5% cap rate validates CBL’s stated valuation framework and suggests the public market may be overly discounting liquidity and asset quality. Refinancing momentum—especially inside a hot CMBS/CLO environment—lowers near-term solvency risk while freeing cash flow for dividends and repurchases. However, high leverage, low-quality Class B/C mall exposure, and tariff-driven retail pressure still present structural headwinds. Management’s capital allocation discipline will be critical given elevated compensation and mixed messaging on reinvestment versus repurchases. Rate cuts would meaningfully improve FFO and sentiment, but reliance on macro tailwinds is a risk. The setup offers asymmetric optionality: stable refinancing plus selective asset sales could create significant equity value, but missteps could quickly erode that cushion.

Actual Post Content:
An update on $CBL Yesterday, CBL announced the sale of the Promenade Open Air Center for $83 Million. The property was on the books for $39.6 Million less accumulated depreciation of $8.6 Million as of 2024 (closer to $9.9 Million as of June 2025 – see page 113 of the 2024 10-K). Let’s call it $30 Million to make it a round number. Assuming closing costs of $3 Million (just shy of 4% of the sale price) $CBL will realize a gain of $49 Million. Not only is that annoying to the bears on its own, but the Promenade was an unencumbered property (no debt) meaning $CBL can do whatever it wants with the cash. Since REITs are required to pay out 90% of Net Income and $CBL already reports positive income, we can expect about $44 Million to be paid out later this year as a dividend, roughly $1.50 a share. Combined, by the end of the year $CBL will have paid four 0.40 dividends, an 0.80 special, a $1.50 special, and spent $25 Million ($0.80 a share) on repurchases, for a total of $4.70 in cash returns per share. That’s a pretty big return of cash for a REIT (15%). Recently, the bad news has been mounting for the bears. On July 8th, $CBL refinanced the $78 Million Cross Creek Mall loan from 8.19% to 6.856% in a CMBS transaction, and pushed the maturity from August 2025 to 2030. CBL also passed the term loan test in April, and launched a $25 Million share repurchase program in May. I’ll be the first to admit it, the bears are right. CBL has junky properties. Everyone knows this. We can all agree on it. Where I think they go wrong however, is failing to understand the debt is non-recourse and on a property level basis. Unlike the first time around when CBL blew up, 98% of its debt load is attached to individual properties or the term loan properties, none of which is recourse to CBL. Pretty much none of it can 'kill' $CBL unless they do something stupid, because CBL has the optionality of just walking away from properties and handing the keys back to lenders if equity is deeply negative. Take the property level data provided by Intex on the Cross Creek Mall (left). CBL has the mall on the books at $84 Million, less debt of $78 Million so equity is just $6 Million. But this year the property is projected to produce cash flow of $15 Million, less interest expense of $5.3 Million, which is $9.7 Million after interest expense. I’m not saying CBL’s equity is $112 Million ($190 Million Appraisal less $78 Million in Debt), but it’s probably worth more than the $6 Million it is on the books for. My point is, there is more to CBL than meets the eye. A lot of people, many of whom I respect, have jumped to the conclusion that CBL will struggle with its debt load and blow up just like it did a few years ago. They also assert CBL’s NAV of $48 is wrong because the cap rate should be way higher. The Promenade mall was sold at a cap rate of 8.5%, precisely in the midpoint of CBL’s self computed 8-9% range for Open Air Centers, and CBL has consistently been pushing out maturities and refinancing at lower rates. They’re right that CBL’s properties are junk, but what if it doesn’t matter? The leveraged loan / CMBS markets are putting up record volume, totally red hot. CBL's own term loan is trading at 94 cents on the dollar, and is being snatched up in new CLOs (right). I don’t like everything about CBL. I think the executive compensation of $11 Million is too high, and I think they should use more of their $350 Million cash pile to buy back stock. I also didn’t like this line in the release: 'The sale generates significant cash proceeds that we intend to put to work at higher cash yields as part of our portfolio optimization strategy. This strategy allows us to harvest undervalued assets in our portfolio and reinvest the cash to grow NOI, FFO and cash flow', as I think they should spend the entire proceeds on repurchases (although maybe they are playing 4-D chess so they don’t move the stock). Still, there is a price for everything. The bottom line is $CBL now has $11 in cash a share and a very flexible balance sheet. While the tariffs are a headwind and malls are a difficult industry to be in, you have a rock bottom valuation (4.5x FFO) and red hot demand for CMBS / CLOs which is enabling CBL to consistently refinance at lower rates, despite the warnings of the bears who seem to think the debt cannot be refinanced. If you’re a bull, all you need is for the company to continue paying off debt, buying back stock, and opportunistically refinancing / selling properties as they have been over the last 3 years. If you’re short, you kinda need everything to go right. You need management to do something really stupid with the cash pile, you need horrific tariff policy to destroy retail, you need the CLO / CMBS market to turn ice cold from its current red hot state so CBL isn't able to keep refinancing lower, and most importantly, you need absolutely zero rate cuts since they would be jet fuel for $CBL’s $700 Million Floating Rate Term loan.

URL: https://x.com/blondesnmoney/status/1947745263243944074